Table 1 Clinical characteristics of survivors
1st year group | 2nd year group | 3rd year group | |||
|---|---|---|---|---|---|
N (%) | N (%) | N (%) | p valuea) | ||
Age (years) | Median | 50.0 | 51.8 | 52.1 | 0.010 |
<41 | 63 (10.8) | 23 (7.0) | 15 (6.5) | ||
41–50 | 255 (43.8) | 126 (38.2) | 88 (38.3) | ||
51–60 | 205 (35.2) | 132 (40.0) | 87 (37.8) | ||
>60 | 59 (10.1) | 49 (14.8) | 40 (17.4) | ||
Stage of disease | 0.105 | ||||
0 | 86 (14.7) | 37 (11.2) | 28 (12.1) | ||
I | 250 (42.8) | 156 (47.4) | 107 (46.3) | ||
II | 190 (32.5) | 101 (30.6) | 60 (26.0) | ||
III-IV | 58 (9.9) | 35 (10.6) | 36 (15.6) | ||
Menstrual status | 0.383 | ||||
Premenopausal | 350 (60.1) | 195 (59.0) | 148 (64.6) | ||
Postmenopausal | 232 (39.9) | 135 (40.9) | 81 (35.4) | ||
Breast surgery | 0.630 | ||||
Breast-conserving surgery | 541 (92.6) | 302 (91.2) | 210 (90.9) | ||
Mastectomy | 43 (7.4) | 29 (8.8) | 21 (9.1) | ||
Axillary surgery | 0.206 | ||||
None | 62 (10.7) | 27 (8.2) | 25 (10.9) | ||
Sentinel node dissection | 293 (50.3) | 190 (57.4) | 128 (55.9) | ||
Axillary node dissection | 227 (39.0) | 114 (27.3) | 76 (33.2) | ||
Radiotherapy field | 0.905 | ||||
Breast only | 435 (74.4) | 251 (75.6) | 174 (75.3) | ||
Breast and regional nodes | 150 (25.6) | 81 (24.4) | 57 (24.7) | ||
Chemotherapy | 0.469 | ||||
No | 211 (36.3) | 125 (37.8) | 75 (32.8) | ||
Yes | 371 (63.7) | 206 (62.2) | 154 (67.2) | ||
Hormone therapy | <0.001 | ||||
No | 163 (29.1) | 64 (19.5) | 43 (18.6) | ||
Yes | 397 (70.9) | 265 (80.5) | 188 (81.4) | ||
Target therapy | 0.855 | ||||
No | 507 (88.9) | 294 (89.4) | 203 (87.9) | ||
Yes | 63 (11.1) | 35 (10.6) | 28 (12.1) | ||